Overview
Analysis
ICPT4833277 analysis
Key facts
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases
Go deeper with bond data
Access the most important data for bonds including coupon rates, issue ratings, redemption data and more.